OBJECTIVE: To investigate the alteration of T-lymphocyte subsets and NK activity in patients with squamous cell carcinoma of pharynx and larynx. METHOD: T-lymphocyte subsets and NK activity were determined by flow cytometry in 123 patients with squamous cell carcinoma of pharynx and larynx. Blood samples of 36 nontumor patients were used as control. RESULT: The total T lymphocytes were lower in patients with squamous cell carcinoma of pharynx and larynx than control group significantly (P < 0.05). The levels of helper lymphocyte subsets were little lower than those in control group(P > 0.05). On the other hand, the levels of suppressor lymphocytes in patients were higher than those in the control group (P < 0.05). Therefore, the CD4/CD8 ratios in patients were lower than those of the control group statistically (P < 0.05). There was no statistical difference in activated T lymphocytes and total B lymphocytes (P > 0.05), but NK activity in patients were lower than those in control group significantly (P < 0.01). There was no statistical difference in total T lymphocytes between stage I-II and stage III--IV (P > 0.05). The levels of helper lymphocyte subsets in stage I-II patients were little higher than in stage III-IV patients (P > 0.05), but the levels of suppressor lymphocytes in stage I-II patients were lower than in stage III-IV patients (P < 0.01). The CD4/CD8 ratios in stage I-II patients were significantly higher than in stage III-IV patients (P < 0.01). The levels of total B lymphocytes in stage I-II patients were significantly higher than in stage III-IV patients (P < 0.05). The activated T lymphocytes and NK activity did not changed statistically (P > 0.05). CONCLUSION The immune function in patients with squamous cell carcinoma of pharynx and larynx is disordered and lower. With advanced stage disease, not only the cellular immune function in patients decrease gradually, but also the humoral immunity is lower. Analyzing T-lymphocyte subsets and NK activity determined by flow cytometry would be easy and helpful to evaluate the immunologic condition of every patient.
Adult ; Aged ; Carcinoma, Squamous Cell ; immunology ; metabolism ; Case-Control Studies ; Female ; Flow Cytometry ; Humans ; Killer Cells, Natural ; immunology ; Laryngeal Neoplasms ; immunology ; metabolism ; Male ; Middle Aged ; Pharyngeal Neoplasms ; immunology ; metabolism ; T-Lymphocyte Subsets ; immunology

OBJECTIVETo explore the efficacy and safety of pemetrexed in the treatment of relapsed primary central nervous system lymphoma (PCNSL).

METHODSSeven cases with relapsed PCNSL admitted in our hospital between August 2012 and August 2013 were retrospectively reviewed.

RESULTSOf the 7 relapsed cases, ectopic recurrence occurred in 3, in situ recurrence in 3 and leptomeningeal metastasis in 1. Patients with relapsed PCNSL were administered with high-dose pemetrexed (900 mg/m²) once for every 3 weeks and supplemented with folic acid and vitamin B₁₂. Complete remission was obtained in 2 patients, partial remission in 3 patients and progressive disease in 2. The overall response rate was 71.4% (5/7). The main adverse reactions were myelosuppression and gastrointestinal reaction.

CONCLUSIONTreatment of relapsed PCNSL is difficult, and its prognosis is very poor. Pemetrexed therapy is a meaningful trial.

Adult ; Aged ; Central Nervous System Neoplasms ; drug therapy ; pathology ; Female ; Glutamates ; administration & dosage ; adverse effects ; therapeutic use ; Guanine ; administration & dosage ; adverse effects ; analogs & derivatives ; therapeutic use ; Humans ; Lymphoma, Large B-Cell, Diffuse ; drug therapy ; pathology ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; Pemetrexed ; Prognosis ; Retrospective Studies